Eli Lilly Joins Tech Players In The $1T Market Capitalization Club

• Eli Lilly is now the first healthcare company to cross the $1 trillion valuation benchmark.
• LLY stock hit as high as $1,061.17 on Friday before paring back gains.
• The company is now looking forward to the launch of its oral GLP-1 drug, Orforglipron, next year to boost market share.

Eli Lilly & Co. (LLY) hit a market capitalization of $1 trillion on Friday after its shares rose as much as 1.7% on optimism surrounding the company’s GLP-1 category of drugs.

With the rise, Lilly is now the first healthcare company to cross the $1 trillion valuation benchmark, joining technology companies including Tesla. The stock hit as high as $1,061.17 on Friday before paring back gains and bringing down market valuation to below $1 trillion.

The company’s GLP-1 drugs, Zepbound, used for weight loss, and Mounjaro, approved for diabetes treatment, have driven investor appetite and pushed its share price by about 40% this year. In the three months through the end of September, the company reported combined Zepbound and Mounjaro revenue of about $10.1 billion. While Mounjaro revenue increased 109% to $6.52 billion in the quarter, Zepbound revenue increased 185% to $3.59 billion.

Pharma Boom, Pipeline Aid Growth

Overall, pharma stocks have had a good run over the past few months. The S&P 500 pharmaceutical index gained 17% over the last month and by about 31% over the past six months.

Earlier this month, Lilly also inked an agreement with the White House, agreeing to lower the prices of its blockbuster drugs in return for a three-year exemption from potential tariffs and access to Medicare patients. The company is also looking forward to the launch of its oral GLP-1 drug, Orforglipron, next year to boost market share.

How Did Stocktwits Users React?

On Stocktwits, retail sentiment around LLY stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.

LLY stock rose 37% this year and by 41% over the past 12 months. 

Also See: Novo’s Obesity Drug Patients Granted Compensation In Denmark Over Rare Eye Disease Linked To Wegovy, Ozempic

For updates and corrections, email newsroom[at]stocktwits[dot]com